These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32090863)

  • 1. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing.
    Mishra R; Krishan S; Siddiqui AN; Kapur P; Khayyam KU; Sharma M
    Tuberculosis (Edinb); 2020 Jan; 120():101902. PubMed ID: 32090863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients.
    Restrepo BI
    Tuberculosis (Edinb); 2016 Dec; 101S():S69-S72. PubMed ID: 27720378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy.
    Mishra AK; Yabaji SM; Dubey RK
    Med Hypotheses; 2018 Jun; 115():77-80. PubMed ID: 29685203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposed drug candidates for antituberculosis therapy.
    An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
    Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
    Yew WW; Koh WJ
    Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the clinical pharmacology of tuberculosis medications.
    Egelund EF; Alsultan A; Peloquin CA
    Clin Pharmacol Ther; 2015 Oct; 98(4):387-93. PubMed ID: 26138226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis.
    Ayodele S; Kumar P; van Eyk A; Choonara YE
    Biomed Pharmacother; 2023 Jun; 162():114588. PubMed ID: 36989709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis.
    Zitko J; Doležal M
    Curr Med Chem; 2018; 25(38):5142-5167. PubMed ID: 28933298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.
    Xu Y; Wu J; Liao S; Sun Z
    Ann Clin Microbiol Antimicrob; 2017 Oct; 16(1):67. PubMed ID: 28974222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.